LPCN vs. ORGS, CEMI, LTRN, LPTX, OPTN, HOWL, IMAB, RAPT, TELO, and KPTI
Should you be buying Lipocine stock or one of its competitors? The main competitors of Lipocine include Orgenesis (ORGS), Chembio Diagnostics (CEMI), Lantern Pharma (LTRN), Leap Therapeutics (LPTX), OptiNose (OPTN), Werewolf Therapeutics (HOWL), I-Mab (IMAB), RAPT Therapeutics (RAPT), Telomir Pharmaceuticals (TELO), and Karyopharm Therapeutics (KPTI). These companies are all part of the "pharmaceutical preparations" industry.
Orgenesis (NASDAQ:ORGS) and Lipocine (NASDAQ:LPCN) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, risk, dividends, valuation, institutional ownership, profitability, earnings, analyst recommendations and community ranking.
In the previous week, Orgenesis and Orgenesis both had 1 articles in the media. Lipocine's average media sentiment score of 1.87 beat Orgenesis' score of 0.47 indicating that Orgenesis is being referred to more favorably in the media.
Lipocine received 342 more outperform votes than Orgenesis when rated by MarketBeat users. However, 100.00% of users gave Orgenesis an outperform vote while only 70.14% of users gave Lipocine an outperform vote.
22.6% of Orgenesis shares are held by institutional investors. Comparatively, 9.1% of Lipocine shares are held by institutional investors. 5.7% of Orgenesis shares are held by insiders. Comparatively, 6.1% of Lipocine shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Orgenesis has a beta of 1.23, suggesting that its stock price is 23% more volatile than the S&P 500. Comparatively, Lipocine has a beta of 1.12, suggesting that its stock price is 12% more volatile than the S&P 500.
Lipocine has a net margin of 0.00% compared to Lipocine's net margin of -1,343.97%. Lipocine's return on equity of 0.00% beat Orgenesis' return on equity.
Lipocine has lower revenue, but higher earnings than Orgenesis.
Summary
Orgenesis and Lipocine tied by winning 6 of the 12 factors compared between the two stocks.
Get Lipocine News Delivered to You Automatically
Sign up to receive the latest news and ratings for LPCN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding LPCN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Lipocine Competitors List
Related Companies and Tools
